BioSpectrum Asia - July 2022
BioSpectrum Asia - July 2022
Magzter GOLDで読み放題を利用する
1 回の購読で BioSpectrum Asia と 9,000 およびその他の雑誌や新聞を読むことができます カタログを見る
1 ヶ月 $9.99
1 年$99.99 $49.99
$4/ヶ月
のみ購読する BioSpectrum Asia
1年 $10.99
保存 7%
この号を購入 $0.99
この問題で
HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?
A successful business model for the pharmaceutical industry is driven by the outsourcing trend, making contract evelopment and manufacturing organisations (CDMOs) an integral component of drug development value chains. Increasing regulatory complexity, high development costs, and fierce competition have driven drug companies to leverage CDMOs to accelerate their go-to-market strategy, and Asia Pacific (APAC) is not an exception. Let’s navigate through prime achievements and potential trends in the APAC CDMO arena which helped the world heal during the pandemic and is further helping to build a resilient health system
Australia recommends COVID-19 booster for eligible 12-15 year old
Other vaccines such as Spikevax (Moderna) and Nuvaxovid (Novavax) are not registered for use as a booster for this age group.
1 min
Wuxi Biologics launches commercial drug product facility for PFS in China
The DP5 is the ninth operational drug product facility in the global network of Wuxi Biologics.
1 min
CEPI, Oxford Vaccine Group evaluate fractional COVID-19 booster vaccines
Trial participants include those who already have received a primary regimen of two doses of CoronaVac at least six months prior to joining the study.
1 min
US picks interdisciplinary teams to address major challenges in cancer
Cancer Grand Challenges aims to provide multiple rounds of funding for multidisciplinary research teams from around the world whose novel ideas have the greatest potential to advance cancer research and improve outcomes for people affected by cancer.
1 min
HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?
A successful business model for the pharmaceutical industry is driven by the outsourcing trend, making contract development and manufacturing organisations (CDMOS) an integral component of drug development value chains. Increasing regulatory complexity, high development costs, and fierce competition have driven drug companies to leverage CDMOs to accelerate their go-to-market strategy, and Asia Pacific (APAC) is not an exception. Let's navigate through prime achievements and potential trends in the APAC CDMO arena which helped the world heal during the pandemic and is further helping to build a resilient health system.
10 mins
Eschewing Myopic Attitude Towards Eye Health
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
9 mins
Why Indian Pharma Must Evolve As 'Value Creator'
As the third-largest drug producer in the world, India is already a major global pharmaceutical player. However, when it comes to the value of production, India ranks fourteenth. A deeper dive into the details reveals an important fact: India is the largest producer and supplier of generic medicines globally, delivering a 20 per cent share. India's pharmaceutical sector has the highest number of USFDA-approved manufacturing plants outside the USA, 3,000 pharmaceutical companies, a network of 10,500 manufacturing facilities and a rich talent pool. So, why does it lag so significantly in deriving value from its assets? Is there an opportunity for the Indian pharmaceutical industry to evolve in a way that moves India up on the value scale by increasing innovation - and what will it take? Let's find out.
4 mins
Obstructive Sleep Apnea brings about a severe economic burden on the country
India has over 50 million sleep apnea patients, 80 per cent of whom are undiagnosed, as per the Lancet Respiratory Medicine 2019 study. Considering the prevalence, OSA brings about a severe economic burden on the country in such a situation. When it comes to COPD, it is the second leading cause of death worldwide, affecting more than 53 million from India. Due to the vulnerability of the lungs, COPD patients become prone to developing cardiovascular issues, and lung cancer, in case of acute exacerbations and even premature death.
5 mins
Spending on TB control programmes had dropped to 2016 levels in 2020 and remains unchanged
Contrary to popular opinion, tuberculosis (TB) has not been eliminated in Singapore.
4 mins
Regulatory bottlenecks such as local QC testing and pre-approval of GMP inspections must go
The APAC pharma and biopharma landscape is rapidly evolving and the market access landscape is increasingly turning complex with the intricate regulatory system.
5 mins
Leveraging big data to create transparency, mitigate risks and operate in real-time is critical
With the innovation boom in Asia and many early-stage assets emerging, the time is ripe for Asian economies to establish cross-border business relationships by systematically tapping potential markets for successful market penetration.
5 mins
From Hazy to Crystal Clear Picture of Compensation Trends
The Life Sciences industry is, indeed, growing at a rapid speed, with every region reporting bonuses and salary increments, as well as a high demand in recruiting new talent. With the talent market becoming increasingly hot, it is critical for industry hiring managers and companies to stay highly aware of compensation trends in the Asia Pacific (APAC) region. Let's assess the current scenario to get a handle on 'what's changed'.
5 mins
BioSpectrum Asia Magazine Description:
出版社: MM Activ Sci-Tech Communication
カテゴリー: Business
言語: English
発行頻度: Monthly
BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:
* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.
BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.
- いつでもキャンセルOK [ 契約不要 ]
- デジタルのみ